Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thinking Outside The Box On Rx Pricing: From Vaccines To Part D Bundling

Executive Summary

Former FDA Deputy Commissioner Sharfstein suggests Vaccine-For-Children model for high value drug purchasing programs during Johns Hopkins drug pricing conference. Bundled payments in Part D is another option put on the table. Medicare head Cavanaugh explains why that option is much harder to accomplish.

You may also be interested in...

Medicare Part D Cost Trends: A Good News/Bad News Story For Biopharma

Despite headlines about soaring drug costs, Medicare Part D beneficiaries are not seeing much if any increase in their out-of-pocket spending. But that doesn’t necessarily mean that costs of the program are stable – which could open up a new area for policy activity in 2017 and beyond.

Lilly, Anthem Singing Same Tune On Value-Based Pricing, Communication Policy

“Project Indy” offers a joint manufacturer/payor perspective on how to enable value based pricing. It also sounds like a potential proposal to CMS to volunteer for a pilot project.

“Frank” Talk On Drug Pricing: HHS Official Sees Value-Based Pricing As Area Of Common Interest

The most likely next step in executive branch action on drug pricing will be testing approaches to value-based pricing in categories where pharmaceutical companies are willing participants. That appears to be the message from an HHS official speaking at a DC policy event.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts